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ANALYSIS FITOKIMIA, AKTIVITI ANTIKANSER DAN AKTIVITI 
ANTIANGIOGENIK TERHADAP EKSTRAK BARRINGTONIA RACEMOSA 
DAN FRAKSINYA 
 
 
ABSTRAK 
 
Barringtonia racemosa Roxb. (Lecythidaceae) ataupun dikenali sebagai putat 
sungai telah digunapakai dalam perubatan tradisional untuk merawat batuk, asma, 
ulser dan cirit-birit. Dalam penyelidikan ini, aktiviti antikanser ekstrak buah B. 
racemosa dan ekstrak biji B. racemosa beserta fraksi-fraksinya telah dikaji secara in 
vitro. Ekstrak dan fraksi yang aktif juga diselidik kesannya ke atas aktiviti 
antiangiogenik dan antioksidan. Buah dan biji B. racemosa diekstrak menggunakan 
teknik pemaseratan dan dipisahkan kepada fraksi-fraksi n-heksana, kloroform, etil 
asetat dan  n-butanol menggunakan teknik pelarut-pelarut. Kesan aktiviti antikanser 
dikaji secara in vitro pada sel kanser payudara (MCF-7) dan sel kanser kolorektal 
(HCT-116) menggunakan asai MTT. Bagi mengkaji mekanisma apoptosis yang 
menyebabkan kematian sel kanser, asai fragmentasi DNA telah digunakan. Fraksi 
bioaktif yang berpotensi ke atas kesan antikanser juga telah digunakan bagi mengkaji 
kesan antiangiogenik secara ex vivo menggunakan teknik asai cerakin gelang aortik 
tikus. Kesan aktiviti antioksidan telah dikaji menggunakan asai DPPH, β-karotene 
dan kuasa penurunan. Hasil kajian ini mendapati fraksi n-butanol B. racemosa 
memberi kesan aktif sitotoksik  ke atas sel MCF-7 (IC50 11.12 ± 1.05 µg/mL). Bagi 
aktiviti antiangiogenik pula, ia menunjukkan perencatan pembentukan salur darah 
mikro pada cerakin gelang aortik tikus sebanyak 50 % pada 34.55 ± 1.34 μg/mL. 
Dalam asai antioksidan, fraksi n-butanol menunjukkan kesan yang sederahana secara 
keseluruhannya. Komposisi kimia yang hadir di dalam fraksi yang aktif, iaitu fraksi 
xxii 
 
n-butanol telah dikesan menggunakan teknik LCMS. Tiga kumpulan triterpenoid 
telah dikesan kehadirannya, iaitu cucurbitacin O, pristimerol dan flaccidin B. 
Penyelidikan ini  telah menujukkan bahawa fraksi n-butanol biji B. racemosa 
menonjolkan kesan aktif sebagai agen antikanser dan antiangiogenik. Malah, 
penyelidikan ini telah berjaya menyokong kenyatan mengenai kegunaannya dalam 
perubatan tradisional bagi menentang penyakit seperti kanser berserta komposisi 
kimianya yang masih belum pernah direkodkan terdahulu.  
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PHYTOCHEMICAL ANALYSIS, ANTICANCER AND ANTIANGIOGENIC 
ACTIVITIES OF BARRINGTONIA RACEMOSA EXTRACTS AND ITS 
FRACTIONS 
 
 
ABSTRACT 
 
Barringtonia racemosa Roxb. (Lecythidaceae) or locally known as putat 
sungai have been used in the treatment of cough, asthma, ulcer and diarrhea as 
traditional remedy. This study investigated anticancer activity of B. racemosa fruit 
extract, seed extract and all its fractions, in vitro. The crude extract and its potent 
bioactive fraction as anticancer agent were also been investigated for their 
antiangiogenic and antioxidant activity. The extraction of fruits and seed were 
carried out by maceration method and further separated into fractions by solvent-
solvent partitioning starting from n-hexane, chloroform, ethyl acetate and n-butanol. 
The anticancer activity was investigated by in vitro cytotoxic on human breast cancer 
cell lines (MCF-7) and human colorectal cancer (HCT-116) by MTT assay. DNA 
fragmentation assay was used to identify the apoptosis mechanism of cell cancer 
death. The ex vivo antiangiogenic properties of potent bioactive anticancer fractions 
were determined using rat aorta ring assay. The antioxidant activities were assayed 
using 1, 1- diphenyl-2- picrylhydrazyl (DPPH), β-carotene linoleic acid bleaching 
and reducing power. The results demonstrated that B. racemosa n-butanol fraction 
exhibited an active cytotoxic effect on MCF-7 cell line (IC50 11.12 ± 1.05 µg/mL). 
The antiangiogenic activity of B. racemosa n-butanol fraction also showed 50 % 
inhibition of microvessels outgrowth in rat aortic rings at 34.55 ± 1.34 μg/mL. In 
antioxidant assay, the n-butanol fraction showed overall moderate activity among all 
assay tested. The chemical constituents present in the most bioactive faction, n-
xxiv 
 
butanol was detected by LCMS method. Three triterpenoid groups namely 
cucurbitacin O, pristimerol and flaccidin B were found to be present in n-butanol 
fraction. This present study indicated that the n-butanol fraction of B. racemosa seed 
extract exhibited active anticancer agent and possessed antiangiogenic properties. 
Thus, this study supported the ethnomedicinal use of the B. racemosa plant against 
cancer like diseases and the compounds identified in this plant have not been 
reported previously.  
 
 
 
1 
 
CHAPTER 1: INTRODUCTION 
 
1.1 Cancer  
 Cancer can affect everyone including a woman and a man, young and old, the 
rich and the poor and today, each of us know at least a family member or a friend 
that has been diagnosed with cancer. So what is cancer? What are the differences 
between a cancer and a tumour? Cancer is a class of diseases characterized by rapid 
proliferation of abnormal cells which can then invade other parts of the body and 
spread out to other organs (National Cancer Institute, 2015). The cancer cells grow 
excessively in the body and a recent study has suggested it can also be considered a 
metabolic disorder (Coller, 2014).   
 
Tumour is an abnormal mass of tissue, also known as neoplasm. A tumour is not 
necessarily a cancer, it may be benign (not cancer), pre-malignant (pre-cancerous), 
or malignant (cancer). Benign tumours do not spread or invade the nearby tissues 
while cancer can spread or invade the nearby tissues and travel to other body parts 
through the blood or the lymph system (National Cancer Institute, 2015).   
 
Cancer cell can be characterised by biopsy or surgery where the tissue or fluid will 
be withdraw and sliced into thin layer for examination under microscope. This 
procedure is known as histological examination and it is the best way of cancer 
detection. This pathology report will reveal the patient information, cell morphology, 
microscopic observation, diagnosis, cancer types and cancer stage (National Cancer 
Institute, 2010).    
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1.2 Epidemiology of cancer 
 An estimated 12.7 million people were diagnosed with cancer across the 
world in 2008, and 7.6 million people died from the disease (WHO, 2011). The 
National Cancer Registry of Malaysia (NCR, 2004) reported a total of 21,464 cancer 
cases diagnosed in Peninsular Malaysia alone and the cases increased from 32,000 in 
2008 to 37,400 in 2012 (The Star, 2014). In 2013, the Ministry of Health Malaysia 
have released the latest Health Facts 2013 and they reported that cancer is the one of 
the top five causes of death and one of the top ten causes of hospitalisation in both 
government and private hospitals. In the year 2014, cancer has overtaken heart 
disease as the number one killer disease in Malaysia.  
 
The National Cancer Registry (NCR) report in 2011 showed the top ten leading 
cancers among the general population in Malaysia (Figure 1.1). The highest 
percentages of cancer were breast cancer (18.1 %), colorectal (12.3 %), lung (10.2 
%), nasopharynx (5.2 %), cervix uteri (4.6), prostate gland (3.4 %) and leukaemia 
(4.1 %), ovary (3.6 %), stomach (3.5 %) and liver (3.3 %). In the United State 
America, the American Cancer Society has reported the list of the most common 
type of cancer diagnosed in the United States in 2015. Table 1.1 showed the number 
of new cases and deaths from the most common cancer types. The cancer rates are 
also seen in developing countries and breast cancer is the frequent diagnosed among 
females.   
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Figure 1.1: Summary statistics of cancers among the general population of Malaysia in 2011 (NCR, 2011). 
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Table 1.1: An estimated number of new cases and death caused by most common 
cancer types in America. 
Cancer Type Estimated New Cases Estimated Deaths 
Bladder 74,000 16,000 
Breast (Female – Male) 231,840 – 2,350 40,290 – 440 
Colon and Rectal 
(Combined) 
132,700 49,700 
Endometrial 54,870 10,170 
Kidney  61,560 14,080 
Leukemia (All Types) 54,270 24,450 
Lung (Including Bronchus) 221,200 158,040 
Melanoma 73,870 9,940 
Non-Hodgkin Lymphoma 71,850 19,790 
Pancreatic 48,960 40,560 
Prostate 220,800 27,540 
Thyroid 62,450 1,950 
 
1.3 Types and treatment of cancer 
 Types of cancer come from the name of tissue or organ where the cancers 
originate. For example, breast cancer starts from breast cells, and prostate cancer 
starts in cells of the prostate. Besides, the cancer name also can be described by the 
types of cell that form cancer cell such as an epithelial cell or a squamous cell 
National Cancer Institute, 2010).  
 
Majority of cancer patients will use surgery, chemotherapy and radiotherapy as 
treatment for cancer and many cancer survivors must cope with the long-term effects 
of treatment, as well as psychological concerns (Siegel et al., 2012). Thus, 
integration of natural product-based drug in cancer treatment may be able to decrease 
the side effects caused by harsh and invasive conventional medical treatment. 
Consequently, in the last few years, the identification and development of natural 
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product-based drug has become a major area in cancer research. In fact 
approximately 74 % of anticancer drugs developed today originated from medicinal 
plants (Lopes et al., 2009). 
 
1.4 Angiogenesis and cancer 
 What makes the tumour becomes a malignant tumour or another word 
cancerous? There is some element which helps the cancer cell growth and spread 
outside of its organ of origin. The key factor of tumour growth and distant metastasis 
is angiogenesis. Angiogenesis is the formation of new blood vessels from pre-
existing vessels. It play a critical role in the progression of a cancer since the new 
blood vessels will deliver all the required nutrient and oxygen to cancer cell, thus 
allowing cancer to spread in other body parts (Folkman, 2002). Therefore, the 
process of angiogenesis is an important target in order to inhibit the cancer growth 
and slowly kill the cancer cell. Nowadays, antiangiogenesis targeting drugs were 
beginning to be the alternative treatment to cure cancer along with application of 
toxin delivery molecules of cytotoxic drugs. 
 
1.5 Potential of Herbal Medicines 
 Plant-based traditional medicine has played a major role in the therapy of a 
spectrum of diseases. The plant medicinal value lies in the its selective chemical 
substances or secondary metabolites, that are capable of producing specific 
physiological action on the human body (Hassan et al., 2009). The use of medicinal 
plants as traditional medicines is important in rural areas of many developing 
countries (Sandhu and Heinrich, 2005; Gupta et al., 2005). Use of herbal extracts 
and nutritional supplements either as alternative or complementary medicine for the 
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treatment of cancer is well documented in various cultures (Dahanukar and Thatte, 
2000). Natural product can be the most prolific source of biologically active 
compounds and play a role in the discovery and development of effective anticancer 
drugs. The rich and diverse plant resources of Malaysia are likely to provide 
effective anticancer agents where in this study, Barringtonia racemosa have been 
selected.  
 
1.5.1 The use of herbal medication in cancer 
 A range of clinical studies have investigated that a spectrum of anticancer 
activities from various herbal medicines can be detected. A study reported that 
among 65 new drugs registered for cancer treatment, 48 drugs were obtained from 
natural products including vincristine and doxorubicin (Safarzadeh et al., 2014). 
Nowadays, traditional Chinese medicines (TCM) have discovered a number of 
anticancer agents, although most of their mechanisms of action have not yet been 
elucidated. Lin et al., (2007) showed that Wedelia chinensis herb containing various 
compounds such as indole-3-carboxylaldehyde and luteolin which capable of 
suppressing prostate cancer activity. In addition, a poplar herbal medicine such as 
turmeric was commonly used by cancer patients to either treat cancer or reduce the 
chemotherapy or radiotherapy effect. It contains 3.14 % by weight of curcumin 
which act as natural anticancer agent and was proven in a few clinical trials (Bar-
Sela et al., 2010).  With the various herbal medicines studies ongoing, systematic 
effort to expedite the discovery and development of new phytomedicines should be 
done intensively. 
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1.6 Barringtonia racemosa 
 Barringtonia racemosa (Figure 1.2) is an evergreen tree found East Africa 
and South East Asia. This plant is widely found in eastern Africa, India, Myanmar, 
Malaysia, Indonesia and southern China. The complete taxonomic classification of 
this plant is listed in Table 1.2.  B. racemosa is a woody tree and is able to reach 20 
m height. The leaves are about 40 cm long and 15 cm wide. The flowers are arranged 
in long spikes and have four white petals with white filament. The fruit is fleshy and 
become fibrous when ripe (Ong, 2004).  
 
Figure 1.2: Barringtonia racemosa tree and fruit. 
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Table 1.2: Taxonomic classification of Barringtonia racemosa (L.) Roxb. 
Taxonomic classification 
Kingdom Plantae 
Phylum Angiosperms 
Class Eudicots 
Order Ericales 
Family Lecythidaceae  
Genus Barringtonia 
Species B. racemosa 
 
 
1.6.1 Medicinal use of Barringtonia racemosa 
 Barringtonia racemosa locally known as putat sungai is a rich source of 
phytomedicine. In Malaysia, the fruit and seed are used to treat asthma, cough, 
abscess, ulcer and diarrhea (Ong, 2004). Of interest, ethnomedical survey has shown 
that the plants are traditionally used in certain remote villages of India to treat ulcer 
and cancer-like diseases (Thomas et al., 2002).  
 
1.6.2 Bioactivities of Barringtonia racemosa 
 Extracts from different parts of the plant have also been reported to show 
various pharmacological activities such as antioxidant, antifungal and anti-tumour 
properties (Nurul Mariam et al., 2008; Hussin et al., 2009; Thomas et al., 2002).  An 
anti-arthritic study done by Patil et al. (2011) demonstrated that a plant-derived 
triterpenoid from B. racemosa fruit extract, bartogenic acid appears to exert 
beneficial effects on multiple pathological manifestations of Complete Freund’s 
Adjuvant (CFA)-induced arthritis in rats.  Other studies demonstrated that the 
methanol extract of B. racemosa fruit showed high antioxidant activity compared to 
a well-established high antioxidant of another local plant, H. sabdariffa (Amran et 
al., 2016). Previous studies strongly proved that the extracts of B. racemosa have 
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strong anti-inflammatory activitiy through carrageenan-induced paw oedema (Shikha 
et al., 2010). It has long been studied that inflammation are related to cancer, and 
there is a strong correlations between the potential anti-inflammatory and 
antiangiogenesis capabilities (Rayburn et al., 2009; Tahergorabi et al., 2013). This 
relationship is due to the similarities of a key molecules involved in inflammatory 
(COX-2 and MCP-1) and angiogenesis (Cardenas et al., 2011). The COX-2 and 
MCP-1 expression are high in angiogenesis during cancer development.  
 
1.6.3 Chemical constituents of Barringtonia racemosa  
 Previous phytochemical studies have revealed the presence of oleanane-type 
isomeric triterpenoids (isoracemosol A and racemosol A) from methanol extract of 
fruits (Gowri et al., 2009), and two neo- clerodane diterpenoids namely nasimaluns 
A and B from ethanol extract of roots of this plant (Hasan et al., 2000). In addition, 
two new triterpenoid sapogenins namely barringtogenic acid and barringtogenol 
have been isolated from the methanol fruit extract of B. racemosa (Anantaraman and 
Pillai, 1956). The chemical structures of isolated triterpenoid constituents were as 
shown as in figure 1.3. Indeed, triterpenoids are highly multifunctional and have 
been showed responsible for antitumor activity in their ability to block nuclear 
factor-kappa B activation, induce apoptosis and angiogenesis in vitro (Petronelli et 
al., 2009).  
 
 Quantitative phytochemical analysis of ethanol extracts of B. racemosa aerial 
parts has shown higher content of total flavonoids (Nurul Mariam et al., 2008). 
Flavonoids including polyphenols are secondary metabolites comprising the 
flavonols, flavones, flavanols, flavanones, anthocyanidins and isoflavonoid 
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subclasses (Kale et al., 2008). Indeed, the structurally related well-characterized 
flavonoid molecule, quercetin, is known to induce apoptosis in different types of 
cancer cells (Xavier et al., 2009). Of interest, the quercetin 3-O-rutinoside is known 
to be present in the methanol extract of fruits of B. racemosa (Samanta et al., 2010).  
 
 In vivo, Zhang et al. 2009 has also showed the significant relationship 
between cytotoxic effects and structurally related flavonols (quercetin, kaempferol, 
myricetin) as well as the molecular mechanisms responsible for the cytotoxic effects 
in a human esophageal squamous cell carcinoma cell line, KYSE-510. Even though a 
few compounds were isolated previously, no further research have been followed up 
using a systematic bioactivity-guided fractionation and purification of the plant fruit 
and seed bioactives to associate them with anticancer activities and the mode of 
action underlying the associated anticancer activities. 
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Figure 1.3: The isolated triterpenoid constituents of B. racemosa. 
 
1.7 Problem statement and rationale of the study 
 The ethnomedicinal use of the fruits and seed of B. racemosa taken raw in 
traditional anticancer treatment is known (Ong, 2004). However, systematic and 
scientific investigations on the phytochemical moiety responsible for these desirable 
anticancer and antiangiogenic activity have yet to be explored and uncovered. The 
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present study is designed to determine the anticancer associated activity of B. 
racemosa; an in-depth preclinical pharmacological and biochemical studies will 
contribute significantly towards drug development in the prevention and/or treatment 
of cancer. These important plant extracts need to undergo complementary scientific 
methodology in order to transit from the traditional herbal medicinal source into 
medicinal products with effective levels of therapeutic value. We are also taking 
advantage of the unique pharmaceutical biodiversity in its constituents to discover 
new effective anticancer drugs from a Malaysian medicinal plant. In this study, local 
tropical plant Baringtonia racemosa is selected to identify for bioactive compounds 
associated with anticancer and antiangiogenic activity, as well as to identify what are 
the compounds present exert their potency against human cancer cells.  
 
1.8 Research Objectives 
 The objectives of this study encompass the following: 
1. To determine the anticancer activity of Barringtonia racemosa fruit extract, 
seed extract and all its fractions using in vitro model.  
2. To determine the antiangiogenic activity of Barringtonia racemosa extract 
and its bioactive fractions associated with anticancer activity.  
3. To determine the antioxidant activity of Barringtonia racemosa extract and 
its bioactive fraction.  
4. To identify the bioactive chemical constituent(s) of Barringtonia racemosa 
most active fraction associated with anticancer and antiangiogenic activity.  
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CHAPTER 2: GENERAL METHODOLOGY 
 
2.1 Introduction 
 This chapter delineates the methodology of this study which aimed to explain 
the process of extraction and fractionation from B. racemosa fruit and seed extracts. 
The present chapter covers starting from plant collection, extraction and separation 
into fractions.  
 
2.2 Materials and methods 
2.2.1 Chemicals and solvents 
 All chemical and solvents from various suppliers were of the highest purity 
needed for each application. The AR grade of methanol, n-hexane, chloroform, ethyl 
acetate and n-butanol were purchased from QReC, New Zealand.  
 
2.2.2 Instrument 
 The plant extraction was evaluated using EYELA rotary evaporator N-1000 / 
N-1100 (USA), Memmert Oven (Germany) and LG refrigerator (Korea).  
 
2.2.3 Plant material 
 The fresh whole fruit and seed of B. racemosa were collected from one 
source in Kepala Batas, Pulau Pinang, Malaysia (GPS coordinate: 5.471, 100.435). 
The plant species was authenticated by a botanist, Dr. Rahmad Zakaria with a 
voucher specimen number 11599. The specimen was preserved in the herbarium 
unit, School of Biological Sciences, Universiti Sains Malaysia.  
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2.2.4 Extraction of crude methanol of fruit and seed B. racemosa extracts 
 The solvent extraction was employed in order to separate the desired 
component using volatile organic solvent that can be removed by rotary evaporator. 
The fruits and seeds were washed, separated from each other and chopped into thin 
slices. The fruit and seed samples respectively were dried in an oven, at an average 
temperature of 40 ± 3 °C. They were then grounded into powder form. Dried powder 
of B. racemosa fruit and seed respectively were macerated with methanol at a ratio 
of dry weight: solvent of 1:10 (w/v) for 24 hours at room temperature. The extracts 
were filtered and evaporated on rotary evaporator to yield the crude methanol 
extract. The crude extracts were stored in amber vial and kept in refrigerator at 2 - 8 
°C until further use.  
 
2.2.5 Fractionation of crude methanol B. racemosa extract by solvent-solvent 
extraction 
 Solvent-solvent partitioning of the plant crude methanol extract was 
performed using separatory funnel to separate compounds based on their polarity and 
relative solubility in two different immiscible liquids. The crude methanol extracts of 
fruit and seed were dissolved in 95 % methanol AR grade and suspended with n-
hexane at a mixture ratio of crude extract: solvent of 1:3 (v/v) respectively. The 
solution was mixed with gentle shaking to yield a brown coloured supernatant and 
the mixture was allowed to settle down for 24 hours. The suspension was extracted 
serially three times each with gradually increasing polarity solvent starting from n-
hexane, chloroform, ethyl acetate to finally n-butanol. The extracts were evaporated 
on rotary evaporator to yield five fractions which are n-hexane fraction, chloroform 
fraction, ethyl acetate fraction, n-butanol fraction and aqueous fraction. 
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CHAPTER 3: IN VITRO CYTOTOXIC STUDIES OF CRUDE METHANOL 
EXTRACT OF BARRINGTONIA RACEMOSA AND ALL ITS FRACTIONS 
 
3.1 Introduction 
 A Cancer cell is an abnormal cell which divides without control and is able to 
invade other healthy tissues or organ. To date, the development of resistance of 
cancer to some cancer drugs or treatments in the market has urged researchers in the 
field in search for a new anticancer drug (Mohammed et al., 2009). Moreover, the 
standard clinical treatments of cancer are often accompanied with severe adverse 
reactions in patients. Alternative anticancer drugs or compounds of lower toxicity 
with specific targeted action on cancer cell on normal cell are needed. There is 
always a need to find a potential and safer drug against cancer and traditional 
medicinal can offer such a source. World Health Organization (WHO) also has been 
taken the step on natural sources in order to work on active or greater activity of 
natural compounds (WHO, 2011). 
 
Natural resources like plant contain many different phytochemicals which play an 
important role as active compounds in pharmaceutics, cosmetics and nutraceutics. 
The phytochemicals present in plant have been acting as a backbone for 
pharmaceutical industry and it was reported that 25 % of the molecules used in 
related industry were build up from natural plant origin (Payne et al., 1991). A 
superior example could be taxol (Paclitaxel) which comes from Taxus brevifolia 
extract that has displayed potent anticancer agent since its discovery in 1971. By 
employing purification of the plant extract and testing each purified fraction for 
anticancer bioactivity, the researcher was able to identify the pure substance 
responsible for the anticancer activity, taxol. This discovery led scientists to work on 
16 
 
the potential of plant as an alternative source to produce new compounds important 
for anticancer activity. 
 
Cytotoxic assays are widely used in pharmaceutical research to screen for cytotoxic 
activity of chemical compounds or mixture of compounds as in natural product. The 
cell based assay is very important to determine if the plant extract have any effect on 
cell proliferation or cytotoxic effect which eventually lead to cell death (Riss et al., 
2013). In developing a therapeutic drug that targets rapidly on dividing cancer cells, 
there are many methods employed for cytotoxic screening and one of the best known 
methods is 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide 
(MTT) assay. The MTT assay is an established and best known colorimetric enzyme 
methods based on a reductive colouring reagent where colour changes in the 
presence of mitochondrial dehydrogenase activities in viable cells can be 
spectroscopically detected.  
 
MTT a yellow water-soluble tetrazole is reduced by mitochondrial dehydrogenase in 
living cell to a purple coloured crystal formazan by NADH. The purple formazan 
formed acts as indicator and represents viable cell due to ability of mitochondrial 
dehydrogenase activities which is present in healthy cell. In turn, the dead cells will 
have lost their ability to reduce the yellow colour of MTT reagent to purple 
formazan. This method is superior because it is easy to perfom, safe, has good 
reproducibility and is widely used in both cell viability and cytotoxicity tests. Since 
reduction of MTT can only occur in metabolically active cells, the viability of the 
cells through colour changes can be measured easily.  
 
17 
 
 
Figure 3.1: Viable cancer cells will reduce the yellow colour of 3-(4, 5-Dimethyl-2-
thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) reagent to a purple 
formazan product. 
 
Apoptosis is a programmed cell death and most of anticancer research has focused 
on apoptosis strategy as it does not induce an inflammatory reaction which can cause 
harm and stress to the normal tissues (Rock and Kono, 2008). The apoptosis 
mechanism can be detected at DNA level by DNA fragmentation and enzyme level 
by caspases activation (Krishnaraja et al., 2014). The DNA fragmentation assay 
allows the determination of DNA degradation upon cells treatment with a potential 
anticancer agent. In apoptotic cells, the ladder pattern of DNA fragment action 
becomes evident following an electrophoresis analysis. 
 
In this chapter, the fruit and seed of B. racemosa were extracted by methanol. A 
further separation into fractions were done by serial extraction solvents of n-hexane, 
chloroform, ethyl acetate, n-butanol and aqueous respectively in the fractionation 
method. The aim is to investigate any potential anticancer properties of the different 
purified components of the plant extracts on two different cancer cell lines namely 
the breast cancer cell line (MCF-7) and colorectal cancer cell lines (HCT-116). The 
most active fraction was then selected and investigated in the DNA fragmentation 
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assay to observe if it exerts apoptosis mechanism of action associated with the 
observed cytotoxic activity. 
 
3.2 Materials and Methods 
3.2.1 Chemicals and solvents 
 Dulbecco's Modified Eagle Medium (DMEM) and Roswell Park Memorial 
Institute medium (RPMI) cell culture media, Fetal Bovine Serum (FBS), 
streptomycin/penicillin (PS) solution, trypsin-EDTA and trypan blue dye solution 
were purchased from Gibco Life Technology, UK. 5-fluorouracil (5-FU), tamoxifen, 
dimethyl sulfoxide (DMSO), sodium bicarbonate (NaHCO3), 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) and phosphate-
buffered saline (PBS) tablet were obtained from Sigma-Aldrich (Sigma Chemical 
Co., St Louis, MO, USA). All solvents were purchased from QReC, New Zealand.  
 
3.2.2 Instrument 
 The cytotoxic assay was evaluated in ESCO biosafety cabinet (USA) using 
Fisher Scientific incubator (Germany), EVOS fluorescence microscope (USA) and 
Thermo Scientific™ Multiskan™ GO Microplate Spectrophotometer (USA). 
 
3.2.3 Extraction of crude methanol of fruit and seed B. racemosa extract 
 The solvent extraction was employed in order to separate the desired 
component using volatile organic solvent that can be removed by rotary evaporator. 
The scheme used for the extraction of B. racemosa is shown in Figure 3.2.  
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3.2.4 Fractionation of crude methanol B. racemosa extract by solvent-solvent 
extraction 
 Solvent-solvent partitioning of the plant crude methanol extract was 
performed using separatory funnel to separate compounds based on their polarity and 
relative solubility in two different immiscible liquids. Fractionation was performed 
as in chapter 2. 
 
3.2.5 Cytotoxic activity of B. racemosa extracts and fractions 
3.2.5(a) Condition of cell lines and culture 
3.2.5(a)(i) Media preparation 
 The breast cancer cell line (MCF7) and colorectal carcinoma cells (HCT-116) 
were purchased from the American Tissues Culture Collection (ATCC, USA). Both 
cells were evaluated in the investigation for cytotoxic activity of the plant crude 
extracts and fractions. The MCF-7 cells were maintained in Dulbecco's Modified 
Eagle Medium (DMEM) while the HCT-116 cells were maintained in Roswell Park 
Memorial Institute medium (RPMI). The media was prepared by dissolving 13.4 g (1 
Packet) of DMEM/RPMI powder (Gibco) and 1.8 g of sodium bicarbonate 
(NaHCO3, Sigma) with 1 L of deionized distilled water (18.2 Ω). Then, the media 
was filtered in sterile condition using a Nalgene rapid-flow Sterile Disposable Filter 
Unit (pore size 0.20 µm, 1000 mL, US). The filtered media was aliquoted into 50 mL 
conical centrifuge tube and kept at 2 - 8 °C. Both cells medium were supplemented 
with 10 % heat inactivated Fetal Bovine Serum (FBS) and streptomycin/penicillin 
(100 µg/ml) in culture flask at 37 °C in 5 % CO2 incubator. Subculture was 
performed every 3 days. 
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3.2.5(a)(ii)  Routine feeding and maintenance  
 The cells morphology and cell density of the breast cancer cell and colorectal 
cancer cell culture were examined regularly and routinely both macroscopically and 
microscopically for any presence of contaminants such as bacteria or fungi. The 
colour and turbidity of the medium were also regularly monitored to maintain the pH 
of medium and nutrients. The medium of the cell culture was changed every two or 
three days depending on growth rate of the cells (Macleod and Langdon, 2004). 
 
3.2.5(a)( iii) Cell subculturing 
 Subculturing cell is a critical part in cell growth and proper sterile technique 
need to be implemented to make sure the cells are healthy and free from any 
contamination. The subculturing process is done once the cells become confluence 
(70 % - 90 %). In subculturing, the old medium was aspirated from the culture flask 
and the attached cells were washed with 5 mL phosphate-buffered saline (PBS). The 
PBS was then aspirated and 700 µL of trypsin was added and incubated in incubator 
for 4-5 minutes. The cells were observed under microscope to detect for detachment. 
After achieving 90 % detachment, a volume of 5 mL pre-warmed complete growth 
medium was added into the flask and the cells were dispersed by pipetting over the 
surface. The cells were then transferred to a 15 mL conical tube and centrifuged at 
200xg for 4-5 minutes. The supernatant was discarded while pellet of the cells was 
resuspended with pre-warmed complete growth medium. About 1 mL of cells was 
transferred into a new flask containing 5 mL of pre-warmed complete growth 
medium. The cells were cultured at 37 °C in a 5 % CO2 incubator. The passage 
number was recorded after subsequent subculture in maintaining the lifetime and 
achieving maximum passage number of the cells (Macleod and Langdon, 2004). 
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3.2.5(b) Cell counting 
 Cell counting was employed in determining the number of cells to calculate 
cell concentration that is required before undergoing any cell based assay. This 
process requires a counting chamber called hemacytometer, a device invented by 
Louis-Charles Malassez to perform blood cell counts in 19
th
 century.  One advantage 
of using the hemocytometer method is that it allows for a variation of technique 
involving the use of Trypan blue dye to differentiate between dead/damaged cells 
and the healthy viable cell of the population. The cells suspension was prepared by 
taking out 100 µL of cell suspension using sterile pipette into a 2.0 mL centrifuge 
tube. About 100 µL of 0.4 % Trypan Blue was added to stain the viable cell. A 10 
µL aliquote of the mixtures were then transferred and filled into both chambers 
underneath the hemacytometer coverslip. The number of cells were viewed and 
counted under microscope at a magnification of 10X. The cells numbers inside four 
squares were counted using following formula (Eq.3.1): 
 
Cells numbers = Total cells counted x dilution factor x 10 000 cells/mL  Eq.3.1 
       no. of squares 
 
3.2.5(c) In vitro cytotoxic activity of crude methanol B. racemosa extracts and its 
fractions 
 The cytotoxic effect of extracts and fractions was evaluated by 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay according to 
the method developed by Mosmann, 1983 with modifications using human breast 
carcinoma cell line (MCF-7) and human colorectal carcinoma cell line (HCT-116). 
Briefly, after being harvested from culture flask, each MCF-7 and HCT-116 cells 
were seeded at 1 x 10
4
 cells/mL  in a 96-well plate containing 100 µL of fresh
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Figure 3.2: Schematic diagram showing the extraction and sequential fractionation of the dried fruit and seed of B. racemosa 
respectively. Cytotoxic assay was performed at crude extract level and each fraction to select the potent anticancer activity.  
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growth media per well. The plate was incubated at 37 °C in 5 % CO2 for 24 hours. 
After incubation, 100 µl of medium containing extracts or fractions at six different 
concentrations (400 µg/ml, 200 µg/ml, 100 µg/ml, 50 µg/ml, 25 µg/ml, 12.5 µg/ml 
and 6.25 µg/ml) respectively were added into 96 well plates and incubated for 48 
hours. Positive control of tamoxifen and 5-Fluorouracil, blank containing medium 
only and negative control containing cell with medium in 1 % DMSO only were 
included. Then, the medium from each well was aspirated and replaced by 20 µL of 
MTT (5 mg/mL) and incubated for 3-4 hours. After that, the crystals were 
solubilized by adding 120 µl of DMSO. After 10 mins of incubation, the absorbance 
was measured at 570 nm ʎmax using a Thermo Scientific™ Multiskan™ GO 
Microplate Spectrophotometer. The inhibition percentages of the cells were 
calculated using following equation (Eq.3.2): 
 
I (%) = [1- (At-A0)/(A1-A0)] x 100    Eq.3.2 
 
Where, I (%) is an inhibition percentage of the cells. At is the absorbance of test 
samples, A0 is the absorbance of a blank and A1 is the absorbance of a negative 
control.  
 
Tamoxifen (MCF-7) and 5-Fluorouracil (HCT-116) served as a positive control. The 
50 % inhibition of each sample was then determined by plotting the values of 
inhibition percentage against respective samples concentration. Consequently, the 
logarithmic regression equations obtained were used to calculate the 50 % inhibition. 
The results were expressed as mean ± SEM (n=3). The plant fraction with lowest 50 
% inhibition was selected for further apoptosis, antiangiogenic, antioxidant and 
phytochemical study.  
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3.2.6 Mechanism of action: Apoptosis studies 
3.2.6(a) DNA fragmentation assay 
 Any sign of apoptosis involvement in the anticancer mechanism can be 
evidenced by a DNA fragmentation pattern. In this study, the potent fraction of plant 
fraction on selective cancer cell line was chosen for evaluating the apoptosis study. 
The breast cancer cell line, MCF-7 (5 x 10
4 
cells per ml) was seeded in cultured 
flasks. After 24 hours incubation, a medium containing n-butanol fractions at IC50 
concentrations (11.5 µg/mL) was added into the flask and incubated for 24 hours. 
The treated cells were collected by centrifugation after trysinization (1000 rpm, 10 
min). The supernatant was discarded. The pellet was resuspended in 1 ml of PBS and 
centrifuged at 1000rpm for 10 minutes. Pellet was collected and extracted using 
Qiagen DNA extraction kit. The extraction of DNA was performed using protocol 
provided by Qiagen DNA extraction kit. The samples were analyzed by 
electrophoresis on a 1.5 % agarose gel and assessed under UV illumination.  
 
3.2.7 Statistical analysis 
 Statistical analysis was carried out by SPSS software version 16.0. All 
experiments values were expressed as means ± SEM (standard error mean). Data 
were analyzed and the comparisons of the samples to positive control were done 
using one-way analysis of variance (ANOVA) followed by post-hoc test treatment of 
Dunnett’s test. The differences were considered significant at P<0.05.  
 
 
 
 
 
 
